Skip to main content
SpringerLink
Log in

Hairy cell leukemia

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder characterized by pancytopenia and variable infiltration of the reticuloendothelial system with “hairy” lymphocytes. HCL is more common in men than women and has a median age of diagnosis of 52 yr. Typically, patients with HCL respond well to purine analog-based therapy. The purpose of this review will be to establish the current status of HCL with respect to its pathophysiology, diagnosis, management, and future directions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958; 13: 609–630.

    PubMed  CAS  Google Scholar 

  2. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 1990; 50: 3605–3609.

    PubMed  CAS  Google Scholar 

  3. Morton LM, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265–276.

    Article  PubMed  CAS  Google Scholar 

  4. Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol 2003; 10: 258–266.

    Article  PubMed  Google Scholar 

  5. Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993; 85: 714–717.

    PubMed  CAS  Google Scholar 

  6. Anderson KC, et al. Hairy cell leukemia: a tumor of preplasma cells. Blood 1985; 65: 620–629.

    PubMed  CAS  Google Scholar 

  7. Burke JS, Sheibani K. Hairy cells and monocytoid B lymphocytes: are they related? Leukemia 1987; 1: 298–300.

    PubMed  CAS  Google Scholar 

  8. MacLerman IC. Gernminal centers. Annu Rev Immunol 1994; 12: 117–139.

    Article  Google Scholar 

  9. Forconi F, et al. Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica 2005; 90: 266–268.

    PubMed  Google Scholar 

  10. Basso K, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004; 199: 59–68.

    Article  PubMed  CAS  Google Scholar 

  11. Ehrhardt GR, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med 2005; 202: 783–791.

    Article  PubMed  CAS  Google Scholar 

  12. Thorselius M, et al. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. Leuk Res 2005; 29: 153–158.

    Article  PubMed  CAS  Google Scholar 

  13. Kamiguti AS, et al. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways. Oncogene 2003; 22: 2272–2284.

    Article  PubMed  CAS  Google Scholar 

  14. Nicolaou F, et al. CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. Blood 2003; 101: 4033–4041.

    Article  PubMed  CAS  Google Scholar 

  15. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2: 339–345.

    PubMed  CAS  Google Scholar 

  16. Tiacci E, et al. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006; 6: 437–448.

    Article  PubMed  CAS  Google Scholar 

  17. Catovsky D, et al. Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Semin Oncol 1984; 11: 362–369.

    PubMed  CAS  Google Scholar 

  18. Cessna MH, et al. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol 2005; 123: 132–138.

    Article  PubMed  Google Scholar 

  19. Vincent AM, et al. Endothelial interactions of hairy cells: the importance of alpha 4 beta 1 in the unusual tissue distribution of the disorder. Blood 1996; 88: 3945–3952.

    Google Scholar 

  20. Csanaky G, et al. Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias. Leukemia 1997; 11: 408–415.

    Article  PubMed  CAS  Google Scholar 

  21. Forster R, et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996; 87: 1037–1047.

    Article  Google Scholar 

  22. Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001; 15: 752–756.

    Article  PubMed  CAS  Google Scholar 

  23. Forster R, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23–33.

    Article  PubMed  CAS  Google Scholar 

  24. Yam LT, Li CY, Finkel HE. Leukemic reticuloendotheliosis. The role of tartrate-resistant acid phosphatase in diagnosis and splenectomy in treatment. Arch Intern Med 1972; 130: 248–256.

    Article  PubMed  CAS  Google Scholar 

  25. Caligaris-Cappio F, et al. Cytoskeleton organization is aberrantly rearranged in the cells of B chronic lymphocytic leukemia and hairy cell leukemia. Blood 1986; 67: 233–239.

    PubMed  CAS  Google Scholar 

  26. Bennett JM, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol 1989; 42: 567–584.

    Article  PubMed  CAS  Google Scholar 

  27. Jongstra-Bilen J, et al. The lymphocyte-specific protein LSP1 binds to F-actin and to the cytoskeleton through its COOH-terminal basic domain. J Cell Biol 1992; 118: 1443–1453.

    Article  PubMed  CAS  Google Scholar 

  28. Schmidt C, et al. CD9 of mouse brain is implicated in neurite outgrowth and cell migration in vitro and is associated with the alpha 6/beta 1 integrin and the neural adhesion molecule L1. J Neurosci Res 1996; 43: 12–31.

    Article  Google Scholar 

  29. Zhang X, et al. Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells. Int J Hematol 2003; 77: 263–273.

    Article  PubMed  CAS  Google Scholar 

  30. Chaigne-Delalande B, et al. RhoGTPases and p53 are involved in the morphological appearance and interferonalpha response of hairy cells. Am J Pathol 2006; 168: 562–573.

    Article  PubMed  CAS  Google Scholar 

  31. Burke JS. The value of the bone-marrow biopsy in the diagnosis of hairy cell leukemia. Am J Clin Pathol 1978; 70: 876–884.

    PubMed  CAS  Google Scholar 

  32. Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood 1994; 83: 497–504.

    PubMed  CAS  Google Scholar 

  33. Ushiki T. Collagen fibers, reticular fibers and elastic fibers. A comprehensive understanding from a morphological viewpoint. Arch Histol Cytol 2002; 65: 109–126.

    Article  PubMed  Google Scholar 

  34. Aziz KA, et al. Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood 2000; 96: 3161–3167.

    PubMed  CAS  Google Scholar 

  35. Aziz KA, et al. The role of autocrine FGF-2 in the distinctive bone marrow fibrosis of hairy-cell leukemia (HCL). Blood 2003; 102: 1051–1056.

    Article  PubMed  CAS  Google Scholar 

  36. Harris NL, et al. Lymphoma classification—from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 2000; 11 (Suppl 1): 3–10.

    Article  PubMed  Google Scholar 

  37. Matutes E, et al. The immunophenotype of splenic lymphoma with villous lymphocytes andits relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83: 1558–1562.

    PubMed  CAS  Google Scholar 

  38. Jansen J, et al. Prognostic significance of immunologic phenotype in hairy cell leukemia. Blood 1984; 63: 1241–1244.

    PubMed  CAS  Google Scholar 

  39. Robbins BA, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993; 82: 1277–1287.

    PubMed  CAS  Google Scholar 

  40. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlolorde oxyadenosine. Blood 1994; 83: 3672–3681.

    PubMed  CAS  Google Scholar 

  41. Jasionowski TM, et al. Analysis of CD10+ hairy cell leukemia. Am J Clin Pathol 2003; 120: 228–235.

    Article  PubMed  CAS  Google Scholar 

  42. de Totero D, et al. Phenotypic analysis of hairy cell leukemia: “variant” cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25). Blood 1993; 82: 528–535.

    PubMed  Google Scholar 

  43. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy- cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 41–56.

    Article  PubMed  CAS  Google Scholar 

  44. Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma 1999; 35: 347–354.

    Article  PubMed  CAS  Google Scholar 

  45. Chen YH, et al. Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol 2006; 125: 251–259.

    Article  PubMed  Google Scholar 

  46. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006; 32: 365–376.

    Article  PubMed  CAS  Google Scholar 

  47. Diez Martin JL, Li CY, Banks PM: Blastic variant of hairy-cell leukemia. Am J Clin Pathol 1987; 87: 576–583.

    PubMed  CAS  Google Scholar 

  48. Hanson CA, Ward PC, Schnitzer B. A multilobular variant of hairy cell leukemia with morphologic similarities to T-cell lymphoma. Am J Surg Pathol 1989; 13: 671–679.

    Article  PubMed  CAS  Google Scholar 

  49. Sun T, et al. Hybrid form of hairy cell leukemia and chronic lymphocytic leukemia. Hematol Oncol 1990; 8: 283–294.

    Article  PubMed  CAS  Google Scholar 

  50. Sainati L, et al. A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990; 76: 157–162.

    PubMed  CAS  Google Scholar 

  51. Imamura T, et al. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. Int J Hematol 2004; 80: 432–434.

    Article  PubMed  Google Scholar 

  52. Kreitman RJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241–247.

    Article  PubMed  CAS  Google Scholar 

  53. Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47: 2066–2076.

    Article  PubMed  CAS  Google Scholar 

  54. Saven A, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918–1926.

    PubMed  CAS  Google Scholar 

  55. Mercieca J, et al. Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leuk Lymphoma 1994; 14 (Suppl 1): 79–83.

    PubMed  Google Scholar 

  56. Else M, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104: 2442–2448.

    Article  PubMed  CAS  Google Scholar 

  57. Savoie L, Johnston JB. Hairy cell leukemia. Curr Treat Options Oncol 2001; 2: 217–224.

    Article  PubMed  CAS  Google Scholar 

  58. Allsup DJ, Cawley JC. The diagnosis and treatment of hairy-cell leukaemia. Blood Rev 2002; 16: 255–262.

    Article  PubMed  CAS  Google Scholar 

  59. Matutes E, et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 1997; 98: 375–383.

    Article  PubMed  CAS  Google Scholar 

  60. Tallman MS, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999; 5: 1665–1670.

    PubMed  CAS  Google Scholar 

  61. Sansville JE, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003; 119: 213–217.

    Article  Google Scholar 

  62. Ravandi F, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107: 4658–4662.

    Article  PubMed  CAS  Google Scholar 

  63. Wheaton S, et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87: 1556–1560.

    Google Scholar 

  64. Filleul B, et al. A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 1994; 8: 1153–1156.

    PubMed  CAS  Google Scholar 

  65. Bastie JN, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma 1999; 35: 555–565.

    Article  PubMed  CAS  Google Scholar 

  66. Guidelines on gramma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. BCSH Blood Transfusion Task Force. Transfus Med 1996; 6: 261–271.

    Google Scholar 

  67. Bouza E, Burgaleta C, Golde DW: Infections in hairy-cell leukemia. Blood 1978; 51: 851–859.

    PubMed  CAS  Google Scholar 

  68. Saven A, et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 1999; 93: 2471–2477.

    PubMed  CAS  Google Scholar 

  69. Zakarija A, Peterson LC, Tallman MS. Splenectomy and treatments of historical interest. Best Pract Res Clin Haematol 2003; 16: 57–68.

    Article  PubMed  Google Scholar 

  70. Stiles GM, et al. Splenectomy for hairy cell leukemia in pregnancy. J Perinatol 1998; 18: 200–201.

    PubMed  CAS  Google Scholar 

  71. Ng JP, et al. Primary splenic hairy cell leukaemia: a case report and review of the literature. Eur J Haematol 1987; 39: 349–352.

    Article  PubMed  CAS  Google Scholar 

  72. Nishii K, et al. Successful treatment with low-dose splenic irradiation for massive splenomegaly in an elderly patient with hairy-cell leukemia. Eur J Haematol 2001; 67: 255–257.

    Article  PubMed  CAS  Google Scholar 

  73. Dearden CE, et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106: 515–519.

    Article  PubMed  CAS  Google Scholar 

  74. Habermann TM, et al. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992; 80: 466–471.

    PubMed  CAS  Google Scholar 

  75. Baer MR, Ozer H, Foon KA. Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia. Br J Haematol 1992; 81: 167–169.

    PubMed  CAS  Google Scholar 

  76. Seymour JF, et al. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995; 9: 929–932.

    PubMed  CAS  Google Scholar 

  77. Pettitt AR. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br J Hoematol 2003; 121: 692–702.

    Article  CAS  Google Scholar 

  78. Cheson BD, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998; 16: 3007–3015.

    PubMed  CAS  Google Scholar 

  79. Jehn U, et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18: 1476–1481.

    Article  PubMed  CAS  Google Scholar 

  80. von Rohr A, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002; 13: 1641–1649.

    Article  Google Scholar 

  81. Juliusson G, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989–995.

    PubMed  CAS  Google Scholar 

  82. Grever M, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974–982.

    PubMed  CAS  Google Scholar 

  83. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102: 810–813.

    Article  PubMed  CAS  Google Scholar 

  84. Thomas DA, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906–3911.

    Article  PubMed  CAS  Google Scholar 

  85. Cervetti G, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004; 73: 412–417.

    Article  PubMed  CAS  Google Scholar 

  86. Quigley MM, et al. CD52 expression in hairy cell leukemia. Am J Hematol 2003; 74: 227–230.

    Article  PubMed  CAS  Google Scholar 

  87. Fietz T, et al. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J 2004; 5: 451–452.

    Article  PubMed  CAS  Google Scholar 

  88. Kreitman RJ, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94: 3340–3348.

    PubMed  CAS  Google Scholar 

  89. Kreitman RJ, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622–1636.

    PubMed  CAS  Google Scholar 

  90. Carson DA, Leoni LM, Hairy-cell leukaemia as a model for drug development. Best Pract Res Clin Haematol 2003; 16: 83–89.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, University College Hospital Galway, Galway, Ireland

    Ronan Swords

  2. Department of Leukaemia — Unit 428, The University of Texas M.D. Anderson Cancer Centre, 1515 Holcombe Blvd, 77030-4009, Houston, TX, USA

    Francis Giles MD

Authors
  1. Ronan Swords
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francis Giles MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francis Giles MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swords, R., Giles, F. Hairy cell leukemia. Med Oncol 24, 7–15 (2007). https://doi.org/10.1007/BF02685898

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02685898

Key Words

Search

Navigation